HMGB1 and myeloid sarcoma: No statistically significant correlations were observed between expression levels or protein levels of HMGB1 in patients with different clinical forms of MS and clinical variables (disease duration, number of relapses in the previous 2 years, and EDSS score at the time of blood collection) nor with radiological variables (number of gadolinium-enhancing lesions at the time of blood extraction) (data not shown).